Top states for electronic Rx ranked by Surescripts
After five years at No. 1 in Surescripts’ Safe-Rx Awards, Massachusetts drops to No. 2 in the rankings of highest e-prescribing use in the nation during 2011.
Surescripts announced that Minnesota achieved the highest rate of e-prescribing use in the nation during 2011 to capture the No. 1 ranking in its seventh annual Safe-Rx Awards. After a five-year run at No. 1, Massachusetts falls to No. 2.
The rankings are determined by an analysis of data that measures electronic prescribing use by physicians, pharmacies and payers in each state. The top 10 states with the highest rates of e-prescribing, according to Surecripts, are:
1. Minnesota
2. Massachusetts
3. South Dakota
4. Delaware
5. New Hampshire
6. Iowa
7. North Carolina
8. Maine
9. Vermont
10. Michigan
Growth in the adoption and use of e-prescribing – which includes prescription routing, utilization of benefit information and utilization of medication history – created the most changes in the rankings over its seven-year history. According to Surescripts, the data indicates that state and federal initiatives to increase the adoption and use of e-prescribing by healthcare providers are significant drivers in e-prescribing’s growth.
Highlights from the rankings include:
- Prescribers in Minnesota routed 61% of prescriptions electronically.
- Massachusetts and New Hampshire have the highest rate of physician adoption at 86%.
- Nine states have more than 70% of physicians electronically routing prescriptions.
- North Dakota made the largest gains year over year, boosting its ranking from No. 47 to No. 18.
- New Hampshire, Nebraska and Minnesota all made double-digit gains in the ranking based on increased use of e-prescribing.
- Nationally, 91% of retail pharmacies are able to receive e-prescriptions.
Go back to the Managed Healthcare Executive eNews newsletter.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More
